Medicine and HealthNature Communications
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
R. Grewal, L. Nguyen, et al.
This important study estimated the effectiveness of monovalent mRNA COVID-19 vaccine booster doses against severe outcomes from the Omicron variant in adults aged 50 and older in Ontario. Conducted by a team of experts, it reveals that booster doses provided strong protection against severe outcomes for at least three months, with insights into the waning effect over time and variations across sublineages.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants
M. Belik, P. Jalkanen, et al.
Medicine and Health
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period
P. T. V. Florentino, F. J. O. Alves, et al.
Medicine and Health
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
A. Saraf, R. Gurjar, et al.
Medicine and Health
Effectiveness of BA.1-and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
T. Arashiro, Y. Arima, et al.
